Autopsy report · NCT03337503
Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
Cause of deathFunding or business
“Sponsor decision to stop the study”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 161 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Santé Cannabis
- Sponsor type
- University, hospital or other
- Conditions
- Chronic Pain
- Interventions
- THC and CDB in a 1 to 1 ratio; Experimental: THC and CBD in a 1 to 2 ratio; High CBD with trace THC oil; placebo
- Participants
- 161
- Sites
- 1
- Countries
- Canada
Trials that died the same way
- Multi-center Complex Atrial Tachycardia High-Resolution Mapping Registry (MATH)
“The sponsor has decided to stop the study” - the Health Crisis at the Healthcare Professionals, Careers and Non-careers, a Month After the Containment Period
“the sponsor decided to stop the study” - Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
“Study has been stopped by sponsor decision.” - Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
“Sponsor decision to terminate the study” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.